Screening North American plant extracts in vitro against Trypanosoma brucei for discovery of new antitrypanosomal drug leads

Abstract

BackgroundHuman African Trypanosomiasis (HAT) is a protozoan parasitic disease caused by Trypanosoma brucei. The disease is endemic in regions of sub-Saharan Africa, covering 36 countries and more than 60 million people at the risk. Only few drugs are available for the treatment of HAT. Current drugs suffer from severe toxicities and require intramuscular or intravenous administrations. The situation is further aggravated due to the emergence of drug resistance. There is an urgent need of new drugs that are effective orally against both stages of HAT. Natural products offer an unmatched source for bioactive molecules with new chemotypes.MethodsThe extracts prepared from 522 plants collected from various parts of the North America were screened in vitro against blood stage trypamastigote forms of T. brucei. Active extracts were further screened at concentrations ranging from 10 to 0.4 μg/mL. Active extracts were also investigated for toxicity in Differentiated THP1 cells at 10 μg/mL concentration. The results were computed for dose–response analysis and determination of IC50/IC90 values.ResultsA significant number (150) of extracts showed >90 % inhibition of growth of trypomastigote blood forms of T. brucei in primary screening at 20 μg/mL concentration. The active extracts were further investigated for dose–response inhibition of T. brucei growth. The antitrypansomal activity of 125 plant extracts was confirmed with IC50 < 10 μg/mL. None of these active extracts showed toxicity against differentiated THP1 cells. Eight plants extracts namely, Alnus rubra, Hoita macrostachya, Sabal minor, Syzygium aqueum, Hamamelis virginiana, Coccoloba pubescens, Rhus integrifolia and Nuphar luteum were identified as highly potent antitrypanosomal extracts with IC50 values <1 μg/mL.ConclusionsLimited phytochemical and pharmacological reports are available for the lead plant extracts with potent antitrypanosomal activity. Follow up evaluation of these plant extracts is likely to yield new antitrypanosomal drug-leads or alternate medicines for treatment of HAT.Electronic supplementary materialThe online version of this article (doi:10.1186/s12906-016-1122-0) contains supplementary material, which is available to authorized users.

Antiprotozoal, antiviral and cytotoxic properties of the nigerian mushroom, hypoxylon fuscum pers. fr. (xylariaceae)

“…For this test, a modification of a method described recently 27 was used. In brief, two days culture of Trypanosoma brucei brucei was diluted in a 96-well microplates, containing Iscove's Modified Dulbecco's medium (IMDM) to obtain 5000 parasites/mL.…”

Inhibitors of ubiquitin E3 ligase as potential new antimalarial drug leads

“…The methods described earlier were used to measure cytotoxicity for Vero and THP1 cells [13, 14]. In brief, four days’ old Vero and THP1 cell cultures were diluted with RPMI medium to 25,000 cells/mL.…”

Sequential Elution of Essential Oil Constituents during Steam Distillation of Hops (<i>Humulus lupulus</i> L.) and Influence on Oil Yield and Antimicrobial Activity

“…The diluted extracts and fractions were subjected to Trypanosoma brucei trypamastigotes assay. Alamar Blue assay was performed as described previously 37 . These assays have been adapted to 384-well micro-plate format.…”

“…The samples with appropriate dilution as mentioned above were added to the T. brucei trypamastigotes cultures. The plates were incubated at 37 and growth of cultured parasites was determined by the Alamar Blue assay as described earlier 37 .…”